Analysts Expect FibroGen Inc (NASDAQ:FGEN) to Post -$0.59 EPS
Analysts forecast that FibroGen Inc (NASDAQ:FGEN) will post earnings of ($0.59) per share for the current quarter, Zacks reports. Five analysts have made estimates for FibroGen’s earnings. The highest EPS estimate is ($0.48) and the lowest is ($0.72). FibroGen reported earnings per share of ($0.50) during the same quarter last year, which suggests a negative year over year growth rate of 18%. The business is scheduled to report its next earnings report on Thursday, November 14th.
On average, analysts expect that FibroGen will report full year earnings of ($0.37) per share for the current year, with EPS estimates ranging from ($0.69) to ($0.07). For the next fiscal year, analysts anticipate that the business will report earnings of ($0.19) per share, with EPS estimates ranging from ($1.75) to $1.40. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover FibroGen.
FibroGen (NASDAQ:FGEN) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $1.26 EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $1.75. The company had revenue of $191.57 million during the quarter, compared to the consensus estimate of $29.03 million. FibroGen had a return on equity of 9.01% and a net margin of 13.90%. The company’s quarterly revenue was up 335.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.28) EPS.
Shares of NASDAQ FGEN traded up $2.13 during mid-day trading on Friday, reaching $43.43. The company had a trading volume of 381,502 shares, compared to its average volume of 559,503. The company has a 50-day moving average price of $44.87 and a two-hundred day moving average price of $46.37. The stock has a market cap of $3.66 billion, a PE ratio of -42.17 and a beta of 1.87. The company has a current ratio of 9.73, a quick ratio of 9.71 and a debt-to-equity ratio of 0.07. FibroGen has a 1-year low of $33.51 and a 1-year high of $61.95.
In related news, CEO Thomas B. Neff sold 18,400 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $45.65, for a total value of $839,960.00. Following the transaction, the chief executive officer now directly owns 2,379,710 shares of the company’s stock, valued at approximately $108,633,761.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Thomas B. Neff sold 39,636 shares of the business’s stock in a transaction that occurred on Thursday, June 20th. The stock was sold at an average price of $44.20, for a total value of $1,751,911.20. Following the completion of the sale, the chief executive officer now owns 2,449,106 shares of the company’s stock, valued at $108,250,485.20. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 238,188 shares of company stock worth $10,651,105. Insiders own 7.83% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. Manchester Capital Management LLC bought a new stake in shares of FibroGen during the 1st quarter worth $39,000. Cornerstone Advisors Inc. increased its holdings in FibroGen by 672.8% in the 1st quarter. Cornerstone Advisors Inc. now owns 796 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 693 shares during the period. Quadrant Capital Group LLC acquired a new position in shares of FibroGen in the 1st quarter valued at $45,000. Captrust Financial Advisors acquired a new position in shares of FibroGen in the 2nd quarter valued at $90,000. Finally, US Bancorp DE lifted its holdings in shares of FibroGen by 79.7% during the 2nd quarter. US Bancorp DE now owns 2,172 shares of the biopharmaceutical company’s stock worth $98,000 after acquiring an additional 963 shares during the period. 69.88% of the stock is currently owned by institutional investors.
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Featured Article: Is it better to buy a fund with a higher or lower NAV?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.